| pubmed-article:17761397 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17761397 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17761397 | lifeskim:mentions | umls-concept:C0543467 | lld:lifeskim |
| pubmed-article:17761397 | lifeskim:mentions | umls-concept:C1337013 | lld:lifeskim |
| pubmed-article:17761397 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:17761397 | lifeskim:mentions | umls-concept:C0303029 | lld:lifeskim |
| pubmed-article:17761397 | lifeskim:mentions | umls-concept:C0023866 | lld:lifeskim |
| pubmed-article:17761397 | lifeskim:mentions | umls-concept:C1552617 | lld:lifeskim |
| pubmed-article:17761397 | lifeskim:mentions | umls-concept:C0282443 | lld:lifeskim |
| pubmed-article:17761397 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:17761397 | pubmed:dateCreated | 2007-9-17 | lld:pubmed |
| pubmed-article:17761397 | pubmed:abstractText | In the present study we investigated the role of radio-guided surgery with Iodine-131 (I-131) in a group of 31 patients with differentiated thyroid cancer (DTC) and loco-regional recurrent disease. The principal inclusion criterion for I-131 radio-guided surgery in our protocol was the presence of an I-131 positive loco-regional disease relapse after previous total thyroidectomy and at least 2 ineffective conventional I-131 treatments. The protocol we used consisted of the following steps. Day 0: all patients were hospitalized and received a therapeutic 3.7 GBq (100 mCi) dose of I-131 after thyroid hormone therapy withdrawal in condition of overt hypothyroidism (serum TSH levels>30 microUI/ml). Day 3: a whole body scan following the therapeutic I-131 dose (TxWBS) administration was acquired. Day 5: neck surgery was performed through a wide bilateral neck exploration using a 15-mm collimated gamma probe, measuring the absolute intra-operative counts and calculating the lesion to background (L/B) ratio. Day 7: post-surgery TxWBS was performed using the remaining radioactivity to evaluate the completeness of tumoral lesions extirpation. The final histologic examination showed the presence of 184 metastatic foci; among them, 98 (53.2%) were evident by both TxWBS and gamma probe evaluation, 76 (41.3%) were demonstrated only by gamma probe, and 10 (5.4%) were negative by both TxWBS and gamma probe evaluation. During follow-up (8 months to 4.9 years, mean 2.8 years), DxWBS, serum Tg levels off l-T4, and US showed absence of loco-regional disease in 25 patients (80.6%) while 6 patients had persistent disease. In conclusion, this protocol allowed us to identify neoplastic foci with high sensitivity and specificity, enabling us to remove loco-regional I-131 disease recurrences resistant to previous conventional I-131 therapies. Furthermore, the gamma probe allowed detection of some additional tumoral foci in sclerotic areas or located behind vascular structures that were not visualized at the pre-surgery TxWBS evaluation. | lld:pubmed |
| pubmed-article:17761397 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17761397 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17761397 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17761397 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17761397 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17761397 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17761397 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17761397 | pubmed:issn | 0753-3322 | lld:pubmed |
| pubmed-article:17761397 | pubmed:author | pubmed-author:ArditoGG | lld:pubmed |
| pubmed-article:17761397 | pubmed:author | pubmed-author:GrossM DMD | lld:pubmed |
| pubmed-article:17761397 | pubmed:author | pubmed-author:MarianiGG | lld:pubmed |
| pubmed-article:17761397 | pubmed:author | pubmed-author:MuzzioP CPC | lld:pubmed |
| pubmed-article:17761397 | pubmed:author | pubmed-author:SalvatoreAA | lld:pubmed |
| pubmed-article:17761397 | pubmed:author | pubmed-author:PelizzoM RMR | lld:pubmed |
| pubmed-article:17761397 | pubmed:author | pubmed-author:RubelloDD | lld:pubmed |
| pubmed-article:17761397 | pubmed:author | pubmed-author:Al-NahhasAA | lld:pubmed |
| pubmed-article:17761397 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17761397 | pubmed:volume | 61 | lld:pubmed |
| pubmed-article:17761397 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17761397 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17761397 | pubmed:pagination | 477-81 | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:meshHeading | pubmed-meshheading:17761397... | lld:pubmed |
| pubmed-article:17761397 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17761397 | pubmed:articleTitle | Iodine-131 radio-guided surgery in differentiated thyroid cancer: outcome on 31 patients and review of the literature. | lld:pubmed |
| pubmed-article:17761397 | pubmed:affiliation | Nuclear Medicine Service, PET Unit, 'S. Maria della Misericordia' Hospital, Istituto Oncologico Veneto (IOV)-IRCCS, Viale Tre Martiri, 140, 45100 Rovigo, Italy. domenico.rubello@libero.it | lld:pubmed |
| pubmed-article:17761397 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17761397 | pubmed:publicationType | Comparative Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17761397 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17761397 | lld:pubmed |
